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ABSTRACT
DEVELOPMENT OF PHARMACOPHORE AND COMFA STUDY
OF RIGID AND FLEXIBLE SIGMA 2 RECEPTOR LIGANDS
by
Hemantbhai Patel
In the present study a pharmacophore and CoMFA model was derived for sigma 2 (62)
receptors by using Sybyl 7.2 Software Package. The CoMFA studies used 22 bioactive
molecules as a training set and 4 molecules as a test set for the o2 receptor ligands. The
geometries and electrostatic charges of all molecules were calculated using various levels
of calculations. The geometry optimization and electrostatic charges of all 26 molecules
were performed by using semiemprical AM1, ab initio HF/6-31G* and density functional
B3LYP/6-31G* in Gaussian 98. The pharmacophore model was derived by using
Distance Comparisions (DISCOtech) from 4 partially to highly active 62 receptor ligands.
The Comparative Molecular Field Analysis (CoMFA) was developed for 22 bioactive 62
receptor ligands to investigate a three dimensional quantitative structural activity
relationship (3D-QSAR) model for 62 receptor ligands. Three CoMFA maps were
developed to compare the electrostatic and steric properties of each calculation and
molecule. The best CoMFA results were obtained by using a training set of 22 molecules
(R2
 = 0.999) from B3LYP/6-31G*. The "leave-one-out" cross validation method gave (q 2
= 0.602) using four optimal components with optimized geometries and atomic charges.
This analysis produced a standard error of estimate of 0.028. The CoMFA results derived
from the B3LYP/6-31G* method were better than those from AM1.
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CHAPTER 1
INTRODUCTION
Sigma (a) receptors were first postulated by William Martin in the mid 1970s [1]. The a
receptor was originally classified as an opioid receptor subtype; then it was identified
with the phencyclidine (PCP) site on the NMDA receptor channel [2]. The discovery of
agents eg. di-tolyl-guanidine (DTG; 25) and various non opioids eg. (haloperidol; 27) led
to the realization that a sites and PCP sites are distinct receptors [3]. Nowadays, a
receptors are well established as non-opioid, non-phencyclidine, and haloperidol sensitive
receptor family with its own binding profile and a characteristic distribution in the central
nervous system (CNS) as well as in endocrine, immune and some peripheral tissues, like
kidney, lung, liver and heart [4]. The a receptors are divided into three subtypes, termed
G1, 02 [5, 6] and 03 receptor [7]. The al receptor has been cloned from tissues of guinea
pig, rat, mouse, and man with the molecular weight of —25 kDa [8-10]. The 02 receptor
has not been cloned yet. The molecular weight was estimated to be about 1821.5 kDa
[11]. The 03 receptor has been shown to modulate tyrosine hydroxylase (TH) and
dopamine synthesis in striatum [12].
Sigma ligands (01 and 02) could be used in the treatment of cocaine abuse,
depression and epileptic disorders [13, 14]. They also have potential as neuroprotective,
antiamnesic, antineoplastic and tumor imaging agents [15, 16]. Both al and 02 sites are
found in high densities in a wide variety of human tumors, including those of the breast,
lung, colon, ovaries and prostate. While 02 sites have been also linked to cellular
1
2proliferation processes and expressed in highly proliferating cells. Several studies have
revealed that a2 receptor have been associated with apoptosis and produce both transient
and sustained increases in calcium ions [17].
There are several selective, high affinity a l ligands available. On the other hand,
very few a2 selective ligands are known; some of them are shown in Figure 1.1 and the
activities of all that compounds are shown in Table 1.1. Haloperidol (27) and di-o-tolyl
guanidine (25) bind with high affinity to al as well as to a2 receptors. Examples of series
of moderate to highly bioactive a2 ligands include: azaperol, related BMY-14802 (4-
amino-1 -arylbutanol s) [18] , vesamicol analogues [19], trishmocubane [20], (E)-8-
benzylidine-5-(3-hydroxyphenyl)-2-methyl morphan-7-ones derivatives (Table 1.2) [21],
N-alkylazacycloheptane derivatives [22], 1-cyclohexylpiperazine derivatives (Table 1.3)
[23], 1-aralkyl-4-benzylpiperidine (Table 1.4) and 1-aralkyl-4-benzylpiperazine
derivatives (Table 1.5) [24], and N-substituted 9-azabicylo [3.3.1] nonan-3α-yl carbamate
analogues [25].
Several molecular modelling studies have been performed to define the binding
pharmacophore model for different classes of a ligands. Manallack used various classes
of molecules to determine the first a l pharmacophore [26]. Glennon and Gund have also
proposed selective al pharmacophore models [27, 28]. Laggner et al. discovered
pharmacophore models built with catalyst software which based upon a series of 23
structurally diverse chemical compounds [29].
A pharmacophore model for the a2 receptor was derived by using GRIND (Grid
Independent Descriptors), however the program does not require ligand alignment.
3PLS models for the 0 2 affinity had r2=0.83 and q2=0.63 were derived using a series of α-
tropanyl derivatives. This model provides internal geometrical relationships within two
hydrophobic areas (hydrophobic-1 and 2) and H-bond donor receptor region with which
ligands establish non covalent bonds [30]. The goal of these computational studies was
the development of a binding model which could accommodate the array of compounds
that have affinity for the (32 receptor,
Figure 1.1 Rigid and Flexible o2
 Receptor Ligands.
Haloperidol (27)
4Table 1.1 Binding and Functional Data of Rigid and Flexible 62 Receptor Ligands [21,
23, 24]
Compounds Configuration σ 1 K i(nM) σ 2 Kt (nM) σ1/σ2
4* (+)-1R,5R 7436 13.4 554.93
6* - 13,6 0.34 40,00
25* - 69 21 3.29
26* - 41,43 0.7 59,19
27 - 2.2 16 0.14
Note: * Indicates included in Pharmacophore Derivation, t Indicates included in CoMFA test set
Table 1.2 Binding and Functional Data of (E)-8-benzylidene-5-(3-hydroxyphenyI)-2-
methylmorphan-7-ones [21]
Compounds Configuration σ1 Ki(nM) σ2 Ki (nM) σ1/σ2
1 (-)-1R,5R 10.5 154 0.07
2f (+)-1R,5R 3063 16.5 185
3 (-)-1R,5R 27.3 35.5 0.77
4* (+)-1R,5R 7436 13.4 554
Note: * Indicates included in Pharmacophore Derivation, t Indicates included in CoMFA test set.
Table 1.3 Binding and Functional Data of 1-cyclohexylpiperazine Derivatives [23]
5
Note: * Indicates included in Pharmacophore Derivation. t Indicates included in CoMFA test set.
Table 1.4 Binding and Functional Data of 1-aralkyl-4-benzylpiperidine Derivatives [24]
6
Note: * Indicates included in Pharmacophore Derivation. i Indicates included in CoMFA test set.
Table 1.5 Binding and Functional Data of 1-aralkyl-4-benzylpiperazine Derivatives [24]
7
Note: * Indicates included in Pharmacophore Derivation, t Indicates included in CoMFA test set.
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CHAPTER 2
PHARMACOPHORE DERIVATION
2.1 Materials and Methods
The calculation in this study was carried out using SYBYL 7.2 [31] molecular modeling
program. All ligands used in this study were built using SYBYL 7.2, and then energy
minimized using the Tripos force field. The geometry optimization and atomic charges
calculation of all molecules used in this study was performed by AM1, HF/6-31G* and
B3LYP/6-31G* methods by using Gaussian 98 program [32]. The pharmacophore was
derived from a set of active compounds by DISCOtech using SYBYL 7.2. DISCOtech
considers all possible mappings of features starting from a set of representative
conformers for each molecule to create a set of alignments. The CoMFA models were
derived using SYBYL 7.2. The CoMFA methodology is a 3D quantitative Structure-
activity relationship (QSAR) technique which ultimately allows designing and predicting
activities of molecules.
2.2 Selection of Ligands
Ligands can interact either covalently or noncovalently with their biological target. The
noncovalent, reversible association of receptor (R) and ligand (L) to form a receptor-
ligand complex (R'L') generally occurs in an aqueous, electrolyte-containing solution
(Equation 2.1).
Rag. + Laq <--> R'L'aq 	(2.1)
9
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Under thermodynamic equilibrium conditions, this reaction is determined by the standard
Gibb's free energy of binding AG ° . This quantity is related to the experimentally
determined association constant KA (or its reciprocal dissociation or inhibition constants,
KD or Ki, respectively) (Equation 2.2),
KA=	 =	 = [R'L']/[R] [L]	 (2.2)
AG° is composed of an enthalpic (AH °) and an entropic (TAS °) portion. T refers to the
absolute temperature. In place of AG ° , the term (binding) affinity is used to describe the
tendency of a molecule to form a complex with another one (Equation 2.3) [33].
ΔG0 = -RT lnKA = ΔH0 - TΔS 	 (2,3)
The compounds for σ 2
 pharmacophore derivation were based on potency, selectivity, and
structural diversity. The pharmacophore for σ2 was defined by using four moderate to
highly active compounds. Among four compounds selected, there were two rigid ligands:
DTG (25) and CB-184 (4) and two flexible ligands: PB-28 (6) and spiro[(2)benzopyran-
1,4'-piperedine] derivative (26). These are listed in Table 1.1 with relative binding
affinity and selectivity values. The relative a2 binding value for all four ligands in Table
1.1 ranges from 0.34 to 13.4 nm. The σ1/σ2 ratio of four compounds in Table 1.1 ranges
from 3 to 555 indicating high selectivity for the σ2 receptor. Binding assays were
performed using [ 3H] di-tolyl-guanidine and [3H] (+) pentazocine [11]. The Ki values
were converted to pKi values by using below Equation 2.4.
11
pKi = -log [Ki]	 (2.4)
2.3 Choice of Initial Conformations
All structures used in this study were generated by building with SYBYL 7.2 using
default bond distances and angles. The energy minimization of all ligands was carried out
by using the tools MAXIMIN2. The tripos force field with a distance-dependent
dielectric function was applied. The maximum number of iterations was set to 100 with
nonbonded (NB) cut off, 8.0 A ° and convergence criterion of 0.05 Kcal/mol of energy
difference between successive iterations.
2.4 Pharmacophore
A pharmacophore is commonly defined as an arrangement of molecular features or
fragments forming a necessary but not sufficient condition for biological activity. A
three-dimensional (3-D) pharmacophore is defined by a critical geometric arrangement of
such features or fragments. Pharmacophores have traditionally been applied singly as
inputs for 3-D database searching, molecular graphics, or automated 3-D design and 3D-
QSAR (Quantitative Structure-Activity Relationship) methods [34]. DISCO (DIStance
Comparison) [35] program; developed by Martin for the purpose of identifying and
systematically aligning common pharmacophoric elements among structurally diverse
ligands was used to derive a pharmacophore model for 02 ligands. DISCOtech identifies
all potential pharmacophoric site points in each molecule of the database. The most
common properties used to describe the potential pharmacophoric fetures of a structure
are:
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(i) Hydrogen bond donor, such as primary/secondary amide, aniline nitrogens and
hydroxyl.
(ii) Hydrogen bond acceptor, for example carbonyl, aliphatic ether and hydroxyl.
(iii) Basic (positively charged at physiological pH 7), for example sp a N aliphatic amines,
hydrazines, guanidines and 2/4 amino pyridines.
(iv) Acidic (negatively charged at physiological pH 7), such as carboxylic acid, acyl
sulfonamide, unsubstituted tetrazole and phenols.
(v) Aromatic, generally (but not always) in the form of ring centroids.
(vi) Hydrophobic, for example certain 5/6 membered aromatic rings, isopropyl, butyl and
cyclopentyl.
The conformer databases were generated for all compounds by DISCOtech. Only
unique conformers were included in databases, the rest were effectively excluded by
Discotech. A master database containing one low energy conformer of each molecule
was utilized as a starting point for the DISCO program [36]. By utilizing DISCO, binding
models were found with two hydrophobic regions and a nitrogen center. These all DISCO
models were then inspected visually in an effort to eliminate models that may not
represent an intuitively rational molecular alignment. The close inspection revealed that
the model shown in Figure 2.1 represents the most rational alignment when considering
the structural diversity of all 22 compounds in the training set. The pharmacophore
triangle includes a nitrogen center and two hydrophobic regions.
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Figure 2.1 DISCOtech Pharmacophore dimensions with hydrophobic (H1 and H2)
regions, nitrogen (N) (a); DISCOtech model with u2 receptOr ligands 6 (b) and 26 (c)
respectively, and also with all four ligands 4, 6, 25 and 26 (d).
CHAPTER 3
CoMFA STUDIES
3.1 Geometry Optimization and Electrostatic Studies
The GAUSSIAN 98 program was used to optimize the conformers derived by
DISCOtech. The calculation of electrostatic charges for these geometries were performed
using semi empirical AM1, density functional B3LYP/6-31G*, and ab initio HF/6-31G*
levels according to Mulliken populations.
3.2 Alignment
An alignment of the training and test set molecules is essential for a CoMFA Studies. The
three optimized calculations were aligned by a match function in SYBYL 7.2 using a
template molecule (25) in Table 1.1 and with the generated pharmacophore in Figure 2.1.
All 26 molecules were aligned with respect to their class and overall geometry by using
the ALIGN DATABASE and 'Field Fit' functions in SYBYL 7.2. The aligned 26
molecules of training and test set are represented in Figure 3.1 according to their
optimization method [37].
14
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Figure 3.1 Alignments Of all 26 molecules optimized using: AM1 (a), HF/6-31G* (b)
and B3LYP/6-31G* (c) methods.
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3.3 CoMFA Model
The CoMFA studies were carried out using the QSAR option of SYBYL 7.2. CoMFA
methodology is based on the assumption that drug-receptor interactions are non-covalent
and change in biological activity correlate with the changes in the steric and/or
electrostatic fields of the drug molecules. The three must-obey rules should be followed
in three dimentional quantitative structure —activity relationship (3D-QSAR) to achieve a
quality CoMFA model: (i) the training set must include a wide population (at least 16
items) of diverse compounds covering at least 4 orders of magnitude of activity; (ii) the
most active compound should be included in the training set; (iii) all biological data must
be obtained by homogeneous procedures [38, 39].
A comprehensive CoMFA analysis was initiated, once model Figure 2.1 was
chosen from the DISCO results as the most appropriate pharmacophore alignment. The
process of developing a suitable CoMFA model required the evaluation of various
training sets utilizing both cross validated and non-cross validated methods. The auto
CoMFA columns were generated using the Tripos Standard CoMFA field class. A sp a
hybridized carbon atom was probed with the default grid spacing, and a charge of +1.0
with a dielectric function of 1 /r; a dielectric constant c of 1 extends 4.0 A beyond every
molecule in all directions. The default of 30 kcal/mol energy cutoff for steric and
electrostatic fields was used [40].
As far as the steric field is concerned, this will increase as the probe atom gets
closer to the molecule. As far as the electrostatic field is concerned, there will be an
attraction between the positively charged probe and electron-rich regions of the molecule,
and repulsion between the probe and electron-deficient regions of the molecule.
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A particular value for the steric energy is then chosen which will define the shape of the
molecule, and the grid points having that value are then connected by contour lines to
define the steric field. This is done for each molecule. A similar process is carried out to
measure the electrostatic interactions between the positively charged probe atom and the
test molecule. Electron-rich and electron-deficient regions for each molecule are then
defined by suitable contour lines. After defining the size, shape and electronic
distribution of series of molecules, the next stage is to relate these properties to the
biological activity of the molecules.
The SAMPLS (SAMple-distance PLS) algorithm developed by Bush and Nachbar
[41] was used to determine q2
 value by "leave-one-out" cross validation. Essentially, it is
an analytical computing process which is repeated over and over again (iterated) to try to
find the best formula relating biological property against the various variables. Once a
formula has been defined, the formula is tested against the structure which was left out.
This is called cross-validation and tests how well the formula predicts the biological
property for the molecule which was left out. The results of this are fed back into another
round of calculations, but now the structure which was left out is included in the
calculations and a different structure is left out. This leads to a new improved formula
which is once again tested against the compound that was left out, and so the process
continues until cross-validation has been carried out against all the structures. At the end
of the process, the final formula is obtained. For each molecule n, this QSAR is results in
the Equation 3.1.
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The indices 1, 2, ..., M reflect the respective grid points, and Sn,1,..., Sn,M and En,1, ..., En,M
describe steric and electrostatic energies at these points. The coefficients αl, ..., αm and [31,
..., βm are obtained from a system of linear equations by partial least-squares analysis
[42]. The predictability of this final equation is quantified by the cross-validated
correlation coefficient r2, which is usually referred to as q 2 PRESS (predictive residual
sum of squares).
The bioactivities of CB-64L (1) and CB-182 (3) were poor as (52 ligands and the
exclusion of both of these compounds from CoMFA model showed a decreased cross-
validated r2 = 0.357 with two components and q 2
 = 0,315 by "Leave-one-out" cross-
validation for set of molecules optimized by HF/6-31G* method. Addition of one more
compound (14); the most inactive 62 ligand to CoMFA training set of HF/6-31G*
optimized molecules showed an increased cross-validated r 2 = 0.446 with three
components and q2 = 0.496 at three components by the "Leave-one-out" cross-validation
method so this CoMFA study was done on 3 orders of Log difference between the most
active and most inactive ligand included in the training set. The best CoMFA results
obtained from these analyses are listed in Table 3.1. The threshold q 2 value of 0.5 is
considered to be minimal for a significantly internally predictive model [43]. The cross-
validation method was utilized to find out predictive power of CoMFA model and to
decide how many components to use for the best model. The 5% rule was considered to
determine this number of optimal components, if q 2 increases by at least 5% upon
increasing the number of components by one, then it is justified to add an additional
component [44]. The Experimental and Predicted bioactivity for all 22 compounds of
Training set are listed in Table 3.2 and for the test set compounds are listed in Table 3.3.
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A Graph of actual activities versus predicted activities of the all compounds are shown in
Figure 3.2.
Table 3.1 Optimal Component Number and q2 by "Leave-One-Out" by SAMPLS [38]
using the Training Set of 22 Molecules
Theory Terminology Comp. 1 Comp. 2 Comp. 3 Comp. 4
AM1 standard error 0.753 0.685 0.687 0.714
q2 (PRESS) 0,222 0.387 0.417 0.404
HF/6-31G* standard error 0.737 0.653 0.646 0.667
q2 (PRESS) 0.254 0.443 0.484 0.480
B3LYP/6-31G* standard error 0.678 0.600 0.517 0.584
q2 (PRESS) 0.368 0.529 0.597 0.602
Table 3.2 Experimental and Predicted Bioactivities (pKi) for the Training Set of 22
Molecules using Various Calculation Methods
Compounds Lit. pKi AM1 HF/6-31G* B3LYP/6-31G*
Predicted pKi
1 -2.188 -2.096 -2.084 -2.156
3 -1.550 -1.597 -1.594 -1.583
4 -1.127 -1.140 -1.148 -1.143
6 0.469 0.476 0,454 0.466
7 0.456 0.378 0.446 0.457
8 0.161 0.162 0.197 0.155
9 0,244 0.233 0.235 0.256
10 0.310 0.258 0.361 0,278
12 -0.666 -0.655 -0.709 -0.643
13 -0.898 -0.900 -0.940 -0.883
14 -2.455 -2.537 -2.454 -2.469
15 -0.230 -0.316 -0.259 -0.234
16 -0.170 -0.161 -0.176 -0.141
17 -0.201 -0.218 -0.113 -0.184
18 -0.480 -0.382 -0.430 -0.458
20 -0.677 -0.687 -0.617 -0.633
21 -0.728 -0.825 -0.700 -0.745
22 -0.146 -0.107 -0.140 -0.148
23 -1.516 -1.415 -1.490 -1.531
24 -1.149 -1.246 -1,222 -1.190
25 -1.322 -1.269 -1.368 -1.288
26 0.155 0.229 0.159 0.112
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Table 3.3 Experimental and Predicted Binding Affinities (pK1) for Test Set of Four
Molecules using Various Calculation Methods
Compounds Lit. pKi AM1 HF/6-31G* B3LYP/6-31G*
2 -1.217 -1.325 -1.262 -1.322
5 0.167 0.226 0.105 0.324
11 -0.401 -0.437 -0.463 -0.587
19 -1.408 -1.218 -1.358 -1.448
The final CoMFA analysis were carried out with CoMFA standard scaling, crossvalidated
q2 , conventional (non-cross validated) r 2, F statistic, Standard error of estimate, Steric and
Electrostatic field co-efficient and fraction of contribution values were calculated and are
presented in Table 3,4. This analysis generated predictive models and CoMFA co-
efficient contour diagrams for the steric and electrostatic potential contributions are
displayed in Figure 3.3. The CoMFA contour maps of steric fields are shown in yellow
and green. The steric regions define the size and shape of the substituents around the
molecule. The green areas (80% contribution) are areas where more bulky substituents
are favoured, and yellow (20% contribution) are areas where less bulk is desired for
higher 62 activity. The contour maps of electrostatic fields are shown in red and blue
color. The red areas (80% contribution) are regions that favor more negative charge, and
blue areas (20% contribution) are areas that favor more positive charge for higher G2
activity.
Table 3.4 QSAR Reports by Non-Crossvalidation using SAMPLS [38] by the Training
Set of 22 Molecules
Theory S.E. R2 F Values Steric. Electro.
AM1 0.080 0.992 (n1=4, n2=21) 623.700 0.303 0.697
HF/3-21G* 0.052 0.996 (n1=4, n2=21) 1493.392 0.358 0.642
B3LYP/3-21G* 0.028 0.999 (n1=4, n2=21) 4610.975 0.301 0.699
Note: Standard error of estimation, R2
 of non-crossvalidation using training set of 22 molecules in Table
1.2-1.5, Steric and Electrostatic contributions to this CoMFA field,
21
Figure 3.2 Graph Of experimental (pK, = -log [K,]) versus predicted biOactivity by the
CoMFA mOdel using different calculation methOds AM1 (a) HF/6-31G* (b) and
B3LYP/6-31G* (c).
Note: *Blue indicates training set while red indicates test set.
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Figure 3.3 CoMFA contour maps derived by σ2  receptor ligands using variOus charge
and geometry Optimization; AM1 (a), HF/6-31G* (b) and B3LYP/6-31G* (c) methods
for Compound 26.
CHAPTER 4
RESULTS AND DISCUSSION
4.1 Pharmacophore
The pharmacophore designed by DISCOtech for σ2 receptor ligands is a three point
arrangement Figure 2.1 that includes a nitrogen atom and two hydrophobic centers. The
two active a2 ligands (6) and (26) are represented in Figure 2.1 (b) and 2.2 (c) with the
pharmacophore dimensions.
4.2 Comparative Molecular Field Analysis
The higher r2 and F-value indicate higher accuracy. The non-crossvalidated PLS analysis
produced the best r2 and standard errors of predicted pKi value. The obtained value of r2 ,
standard error of estimate and F value for all 22 compounds of training set using three
calculation methods is reported in Table 3.4. The relationship between calculated and
predicted pKi values of training set of 22 compounds and a test set of 4 compounds by all
three calculation methods using non-cross validated analysis is also reported in Table 3.2
and Table 3.3 respectively. The Graph of the predicted pKi versus the actual pKi values
are shown in Figure 3.2. The CoMFA model was also cross-validated to confirm the
predictive power of the model. The CoMFA model required three or four optimal
components in different calculations to explain the variance in binding affinity to a2
receptors for this study. A q2 value of more than 0.4 was obtained for all cross validated
analyses. A q2 = 0.602 at 4 component was obtained for B3LYP/6-31G* optimized
geometries and atomic charge calculations; which was higher than those obtained with
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AM1 and HF/6-31G* optimized geometries. The CoMFA models of AM1 optimized
geometries produced lower q2 of 0.417 than those of HF/6-31G* and B3LYP/6-31G*
optimized geometries. The numerical results of a cross validated PLS analysis by "Leave-
One-Out" method using the 22 compounds by all three calculation method are listed in
Table 3.1.
4.3 Validation of the CoMFA Model
The four test compounds were selected; those include: 2 (Table 1.2), 5 (Table 1.3), 11
(Table 1.4) and 19 (Table 1.5); one from each major class of compounds. The range of
binding affinities for the training set was -2.455 to 0.469 log units and the predicted range
of pKi for training set was -2.537 to 0.476 log units for AM1/6-31G* method, -2.454 to
0.454 log units for HF/6-31G* and -2.469 to 0.466 log units for B3LYP/6-31G* method
Table 3.2. The bio-activity of all 22 ligands in the training set was predicted satisfactorily
by all three calculation methods. The predictive utilities of CoMFA model for four
ligands in the test set were considered satisfactory for all three calculations Table 3.3.
4.4 Design of New Ligands
The design of new ligands and prediction of activities is possible by using the spatial
distribution of steric and electrostatic properties of CoMFA contour maps and its
calculation (Figure 3.3). The Spiro [(2) benzopyran-1, 4'-piperidine] derivative (26) was
one of the most potent and highly selective 62 receptor ligands. Six new structures were
suggested in Table 4.1, and predicted pK i values were calculated using AM1, HF/6-31G*,
and B3LYP/6-31G* calculations.
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The AM1 model failed to predict Spiro derivative (26) in the proper ranges (Table 4.1).
The HF/6-31G* and B3LYP/6-31G* model had the higher q 2
 values than the AM1 model
therefore the predicted bioactivities of the new ligands are more probable by these two
models. The CoMFA contour maps were investigated to find out locations where the
modifications of substituent groups are essential to determine the effect on a2 activity.
The CoMFA contour maps of steric fields are shown in yellow and green. The steric
regions define the size and shape of the substituents around the molecule. The green areas
where more bulky substituents are favoured, and yellow where less bulk is desired for
higher G2 activity. The contour maps of electrostatic fields are shown in red and blue
colors. The red regions favor more negative charge, and blue areas favor more positive
charge for higher a2 activity. By using the knowledge of spatial distribution of steric and
electrostatic regions, two locations on the CoMFA maps were investigated to determine
the activity of designed new compounds (Table 4.1). These two important modification
sites were represented by R1 and R2 on Spiro [(2) benzopyran-1, 4'-piperidine] derivative
(26). Six new structures were constructed by changing substituent groups on R1 and R2.
Among these new structures, compounds 27 and 28 had more bulky substituent groups at
R 1
 while compounds 29 and 30 had less bulky substituent groups at R1 compared to the
original ligand (26). By increasing bulk at R1, a drop in the predicted pKi value for
compounds 27 (predicted pKi=0.216) and 28 (predicted pKi=0.211) was observed from
the original ligand 26, using the HF/6-31G* PLS analysis while an increase predicted pKi
value for these two compounds (Table 4.1) was observed using B3LYP/6-31G* PLS
analysis. Compounds 29 and 30 have less bulky substituents at R1, which shows higher
predicted a2 activity for HF/6-31G* and also for B3LYP/6-31G* PLS analysis.
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The predicted pKi value for compounds 29 and 30 are -0.498 and -0.519 for HF/6-31G*
analysis, while -0.651 and -0.022 for B3LYP/6-31G* analysis respectively. The R 1
position of substituent groups falls in the yellow areas where less steric bulk is favored
for higher a2 activity so the values of compounds 29 and 30 clearly suggest that less bulk
at R1 is favorable for higher σ2 activity.
The R2 position of substituent groups falls in the red areas where more negative
charge is favored for higher a2 activity. Compounds 31 and 32 contain negative charged
substituent groups at R2. By introducing a methoxy (-OCH3) group at R2 position in
compound 32 an increase in predicted a2 activity (0.043) for HF/6-31G* and (-0.292) for
B3LYP/6-31G* PLS analysis compared to the bioactivity of the original ligand 26 (Table
4.1). This study suggests that, there is a possibility for future development of a2 receptor
ligands by using small substituent groups at R1 and by using electronegative substituent
groups at R2 to increase selectivity and affinity of these ligands.
Table 4.1 Prediction of Bioactivity for New Ligands
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CHAPTER 5
CONCLUSIONS
This study derived a pharmacophore model that should aid in the design of additional
ligands which possess high affinity and selectivity for the .52 receptor. The predicting
power of the CoMFA models was tested and verified using PLS cross validation. Three
CoMFA contour map were obtained with an alignment of 26 compounds whose
geometries and atomic charge were optimized in AM1, HF/6-31G*, and B3LYP/6-31G*.
This study also suggested that B3LYP/6-31G* optimized geometries produced good
CoMFA models to predict bioactivity of a2 ligands. Two possible sites of modification
for most potent and highly selective (72 ligand (26) were represented by R1 and R2.
Addition of less bulky groups at R1 and more electronegative groups at R2 produced more
active a2 receptor ligands.
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